Medicare can cover Zepbound for sleep apnea, creating a significant opportunity for Eli Lilly
Portfolio Pulse from
Medicare's potential coverage of Zepbound for sleep apnea presents a significant opportunity for Eli Lilly. Currently, Zepbound is not covered by Medicare or many insurance plans for weight loss, costing about $1,000 monthly without insurance.
January 09, 2025 | 4:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Medicare's potential coverage of Zepbound for sleep apnea could boost Eli Lilly's market, as the drug is currently not covered for weight loss and costs $1,000 monthly without insurance.
The potential Medicare coverage for Zepbound in treating sleep apnea could significantly increase Eli Lilly's market reach and sales, as the drug is currently expensive and not widely covered for weight loss.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90